Printer Friendly

MOLECULAR BIOSYSTEMS ACQUIRES LICENSE TO CT IMAGING AGENT TECHNOLOGY

MOLECULAR BIOSYSTEMS ACQUIRES LICENSE TO CT IMAGING AGENT TECHNOLOGY
 SAN DIEGO, Nov. 6 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI), today announced that it has acquired an exclusive worldwide license to a novel computerized tomography ("CT") imaging agent technology from the University of Michigan.
 The CT agent technology was developed by scientists at the University of Michigan at Ann Arbor, and is covered by issued patents and pending applications. The initial product which is currently being developed jointly by researchers at MBI and the University of Michigan, is expected to be a contrast agent for imaging of the liver. This agent may prove to be useful for greatly improving the detection of very small tumors in the liver, using significantly lower doses of the agent than are currently administered. Analysts estimate up to "two million CT liver scans per year are currently performed in the U.S. and that the availability of a liver contrast agent could substantially expand liver CT imaging."
 "We are extremely pleased with our arrangement with the University of Michigan and with the opportunity to work closely with their excellent research team. Acquisition of this CT agent technology represents a substantial market opportunity for MBI," commented Vincent A. Frank, president of MBI. "Combined with our leadership in ultrasound, and our research activities in the magnetic resonance imaging arena, acquiring this CT agent technology is a natural extension of MBI's involvement in medical imaging and a tremendous step forward in MBI's long-term strategy to become a leader in the medical contrast media industry," he further stated.
 Molecular Biosystems Inc., based in San Diego is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound and magnetic resonance imaging. Its flagship product, Albunex(R), is currently in the final stages of the FDA's pre-market approval process. MBI's shares are listed on the New York Stock Exchange under the symbol "MB."
 -0- 11/6/91
 /CONTACT: Beth Wallace of Molecular Biosystems Inc., 619-452-0681/
 (MB) CO: Molecular Biosystems ST: California IN: MTC SU: SE -- SD003 -- 1526 11/06/91 08:04 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:347
Previous Article:BIO-RAD ANNOUNCES THIRD QUARTER SALES AND EARNINGS
Next Article:COUNTRYWIDE'S OCTOBER MORTGAGE ORIGINATIONS TOP $1 BILLION
Topics:


Related Articles
MOLECULAR BIOSYSTEMS RECEIVES ALLOWANCE ON U.S. PATENT FOR ORAL ULTRASOUND AGENT
FDA NOTIFIES MOLECULAR BIOSYSTEMS
EUROPEAN PATENT OFFICE GRANTS MOLECULAR BIOSYSTEMS BROAD ANTISENSE PATENT
GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION
MOLECULAR BIOSYSTEMS ANNOUNCES LICENSE OF ITS ANTISENSE PATENTS
MOLECULAR BIOSYSTEMS INC. SUBMITS PMA AMENDMENT TO FDA
MOLECULAR BIOSYSTEMS INC. ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH ABBOTT LABORATORIES
ImaRx PHARMACEUTICAL CORP. FILES SUIT AGAINST MOLECULAR BIOSYSTEMS INC. OVER TRADE SECRETS
MBI ANNOUNCES ALBUNEX(R) APPROVAL IN JAPAN

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters